1 asset in Severe Early-Onset Obesity-Insulin Resistance Syndrome Due To SH2B1 Deficiency

Therapeutic assets addressing Severe Early-Onset Obesity-Insulin Resistance Syndrome Due To SH2B1 Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dccr Severe Early-Onset Obesity-Insulin Resistance Syndrome Due To SH2B1 Deficiency	Soleno Therapeutics, Inc.	P2	CCC (53)